<DOC>
	<DOCNO>NCT02022657</DOCNO>
	<brief_summary>The primary objective study define mean , variance , dose proportionality tenofovir-diphosphate ( TFV-DP ) dry blood spot result 33 % , 67 % , 100 % daily dose 200mg emtricitabine 300mg tenofovir disoproxil fumarate ( Truvada® ) . With information , model establish predict adherence rate TFV-DP use DBS . Forty-eight healthy HIV-uninfected adult participant low risk HIV infection randomize one 6 sequence consist two directly observe dose regimen , 33 % /67 % , 33 % /100 % , 67 % /33 % , 67 % /100 % , 100 % /33 % , 100 % /67 % dose regimen last approximately 12 week , separate approximately 12 week washout period . DBS collect regular interval , include washout . The hypothesis study level TFV-DP DBS predict adherence rate precede 1-3 month .</brief_summary>
	<brief_title>Pre-Exposure Prophylaxis ( PrEP ) Adherence Monitoring Using Dried Blood Spots</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Ambulatory 1850 year old adult . Enrollment target approximately half woman approximately one third AfricanAmericans one third Latino . 2 . Ability comply study procedure , include directly observe dose visit availability use audiovideo stream technology . 1 . Inability give inform consent 2 . A minimum scalp hair length 2 cm occipital region . 3 . Pregnancy plan become pregnant unwillingness use birth control 4 . Current breastfeeding . 5 . High risk HIV1 infection ( example : sexually active HIV infect partner ; men sex men may engage condomless intercourse HIVinfected partner partner unknown status study ; male females exchange sex money , shelter , gift ; active injection drug use last 12 month ; newly diagnose sexually transmit infection last 6 month ) 6 . Positive screen HIV+ ELISA suspect acute HIV infection opinion clinician . ( example sign symptom acute HIV infection include combination fever , headache , fatigue , arthralgia , vomit , myalgia , diarrhea , pharyngitis , rash , night sweat , adenopathy cervical inguinal ) 7 . Positive Hepatitis B ( HBV ) surface antigen test screen 8 . Active psychiatric illness , social condition , alcohol/drug abuse , opinion investigator , would interfere study requirement . 9 . History nontraumatic , pathologic bone fracture 10 . Glomerular Filtration Rate ( GFR , creatinine clearance ) &lt; 60 ml/min ( MDRD equation ) . 11 . Urine dipstick protein ≥ 2+ 12 . Total bilirubin and/or hepatic transaminase ( ALT AST ) ≥ 2.5x upper limit normal 13 . Absolute neutrophil count ≤ 1,500/mm3 , platelet count ≤ 100,000/mm3 , hemoglobin ≤ 10 g/dL . 14 . Medical condition alters red blood cell kinetics include hemoglobinopathy active hemolysis . 15 . Any laboratory value uncontrolled medical condition would interfere study condition , heart disease and/or cancer . 16 . Contraindicated concomitant medication ( include investigational agent , aminoglycosides , ganciclovir/valganciclovir , chronic highdose acyclovir/valacyclovir , cyclosporine , amphotericin B , foscarnet , cidofovir , product similar active ingredient study medication ( Truvada® ) include ATRIPLA® , COMPLERA® , EMTRIVA® , VIREAD® ; drug contain lamivudine adefovir , close analog Emtricitabine ( FTC ) tenofovir , respectively ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pre exposure prophylaxis</keyword>
	<keyword>Dried blood spot</keyword>
</DOC>